Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use

Joanna K. Law, Chris N. Andrews, Robert Enns

Research output: Contribution to journalArticle

Abstract

Background: Approved indications of intravenous (IV) proton pump inhibition (PPI) are limited to treatment of reflux esophagitis in patients unable to tolerate oral medications and for patients with pathologic hypersecretory states. Objectives: IV PPIs are commonly used after endoscopic evaluation of patients with high-risk endoscopic stigmata (HRES) of nonvariceal upper GI bleeding (NVUGIB). There appears to have been an expansion of indications of this drug at many centers. Design: All consecutive patients receiving IV PPI (pantoprazole) between 2 study periods, (1) when pantoprazole was restricted to the gastroenterology service and (2) when it was unrestricted, were reviewed. Setting: Tertiary care university hospital. Patients: All receiving IV PPI. Interventions: IV PPI utilization. Main Outcome Measurements: Percentage of patients receiving IV PPI for indications other than bleeding during 2 time periods. Results: In the early period, 217 patients (67.30% male) received IV PPI on 218 occasions compared with 516 patients (65.31% male, P = .61) in the later period on 613 occasions. In the early group, 93.12% of 217 patients received IV PPI for NVUGIB compared with 56.12% of 516 patients (P < .0001) with 18% of patients receiving IV PPI for nothing by mouth status and 13% for abdominal pain in the later group. A total of 153 (70.18%) patients in the early group underwent upper endoscopy compared with only 275 (44.86%) patients in the later group; 84 of these 153 patients (54.90%) were already on IV PPI at the time of endoscopy in the early group compared with 253 (92.00%, P < .0001). Conclusions: IV PPI use has escalated at our hospital and is being prescribed in patients before endoscopy with fewer patients noted to have HRES on endoscopy.

Original languageEnglish (US)
Pages (from-to)3-9
Number of pages7
JournalGastrointestinal Endoscopy
Volume69
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Proton Pumps
Endoscopy
Christianity
Hemorrhage
Peptic Esophagitis
Gastroenterology
Tertiary Healthcare

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

Intravenous proton pump inhibition utilization and prescribing patterns escalation : a comparison between early and current trends in use. / Law, Joanna K.; Andrews, Chris N.; Enns, Robert.

In: Gastrointestinal Endoscopy, Vol. 69, No. 1, 01.2009, p. 3-9.

Research output: Contribution to journalArticle

@article{9fc7e8f54dfa461e9487b0aff1e78a08,
title = "Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use",
abstract = "Background: Approved indications of intravenous (IV) proton pump inhibition (PPI) are limited to treatment of reflux esophagitis in patients unable to tolerate oral medications and for patients with pathologic hypersecretory states. Objectives: IV PPIs are commonly used after endoscopic evaluation of patients with high-risk endoscopic stigmata (HRES) of nonvariceal upper GI bleeding (NVUGIB). There appears to have been an expansion of indications of this drug at many centers. Design: All consecutive patients receiving IV PPI (pantoprazole) between 2 study periods, (1) when pantoprazole was restricted to the gastroenterology service and (2) when it was unrestricted, were reviewed. Setting: Tertiary care university hospital. Patients: All receiving IV PPI. Interventions: IV PPI utilization. Main Outcome Measurements: Percentage of patients receiving IV PPI for indications other than bleeding during 2 time periods. Results: In the early period, 217 patients (67.30{\%} male) received IV PPI on 218 occasions compared with 516 patients (65.31{\%} male, P = .61) in the later period on 613 occasions. In the early group, 93.12{\%} of 217 patients received IV PPI for NVUGIB compared with 56.12{\%} of 516 patients (P < .0001) with 18{\%} of patients receiving IV PPI for nothing by mouth status and 13{\%} for abdominal pain in the later group. A total of 153 (70.18{\%}) patients in the early group underwent upper endoscopy compared with only 275 (44.86{\%}) patients in the later group; 84 of these 153 patients (54.90{\%}) were already on IV PPI at the time of endoscopy in the early group compared with 253 (92.00{\%}, P < .0001). Conclusions: IV PPI use has escalated at our hospital and is being prescribed in patients before endoscopy with fewer patients noted to have HRES on endoscopy.",
author = "Law, {Joanna K.} and Andrews, {Chris N.} and Robert Enns",
year = "2009",
month = "1",
doi = "10.1016/j.gie.2008.04.053",
language = "English (US)",
volume = "69",
pages = "3--9",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Intravenous proton pump inhibition utilization and prescribing patterns escalation

T2 - a comparison between early and current trends in use

AU - Law, Joanna K.

AU - Andrews, Chris N.

AU - Enns, Robert

PY - 2009/1

Y1 - 2009/1

N2 - Background: Approved indications of intravenous (IV) proton pump inhibition (PPI) are limited to treatment of reflux esophagitis in patients unable to tolerate oral medications and for patients with pathologic hypersecretory states. Objectives: IV PPIs are commonly used after endoscopic evaluation of patients with high-risk endoscopic stigmata (HRES) of nonvariceal upper GI bleeding (NVUGIB). There appears to have been an expansion of indications of this drug at many centers. Design: All consecutive patients receiving IV PPI (pantoprazole) between 2 study periods, (1) when pantoprazole was restricted to the gastroenterology service and (2) when it was unrestricted, were reviewed. Setting: Tertiary care university hospital. Patients: All receiving IV PPI. Interventions: IV PPI utilization. Main Outcome Measurements: Percentage of patients receiving IV PPI for indications other than bleeding during 2 time periods. Results: In the early period, 217 patients (67.30% male) received IV PPI on 218 occasions compared with 516 patients (65.31% male, P = .61) in the later period on 613 occasions. In the early group, 93.12% of 217 patients received IV PPI for NVUGIB compared with 56.12% of 516 patients (P < .0001) with 18% of patients receiving IV PPI for nothing by mouth status and 13% for abdominal pain in the later group. A total of 153 (70.18%) patients in the early group underwent upper endoscopy compared with only 275 (44.86%) patients in the later group; 84 of these 153 patients (54.90%) were already on IV PPI at the time of endoscopy in the early group compared with 253 (92.00%, P < .0001). Conclusions: IV PPI use has escalated at our hospital and is being prescribed in patients before endoscopy with fewer patients noted to have HRES on endoscopy.

AB - Background: Approved indications of intravenous (IV) proton pump inhibition (PPI) are limited to treatment of reflux esophagitis in patients unable to tolerate oral medications and for patients with pathologic hypersecretory states. Objectives: IV PPIs are commonly used after endoscopic evaluation of patients with high-risk endoscopic stigmata (HRES) of nonvariceal upper GI bleeding (NVUGIB). There appears to have been an expansion of indications of this drug at many centers. Design: All consecutive patients receiving IV PPI (pantoprazole) between 2 study periods, (1) when pantoprazole was restricted to the gastroenterology service and (2) when it was unrestricted, were reviewed. Setting: Tertiary care university hospital. Patients: All receiving IV PPI. Interventions: IV PPI utilization. Main Outcome Measurements: Percentage of patients receiving IV PPI for indications other than bleeding during 2 time periods. Results: In the early period, 217 patients (67.30% male) received IV PPI on 218 occasions compared with 516 patients (65.31% male, P = .61) in the later period on 613 occasions. In the early group, 93.12% of 217 patients received IV PPI for NVUGIB compared with 56.12% of 516 patients (P < .0001) with 18% of patients receiving IV PPI for nothing by mouth status and 13% for abdominal pain in the later group. A total of 153 (70.18%) patients in the early group underwent upper endoscopy compared with only 275 (44.86%) patients in the later group; 84 of these 153 patients (54.90%) were already on IV PPI at the time of endoscopy in the early group compared with 253 (92.00%, P < .0001). Conclusions: IV PPI use has escalated at our hospital and is being prescribed in patients before endoscopy with fewer patients noted to have HRES on endoscopy.

UR - http://www.scopus.com/inward/record.url?scp=58049204464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58049204464&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2008.04.053

DO - 10.1016/j.gie.2008.04.053

M3 - Article

C2 - 18718583

AN - SCOPUS:58049204464

VL - 69

SP - 3

EP - 9

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 1

ER -